BioHarvest appoints former Israeli health chief Hezi Levy to board
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief Hezi Levy to the board effective immediately. David Tsur will step down from its board of directors after more than four years of service, the company said in a statement.
BioHarvest Sciences CEO reflects on milestone year in shareholder letter
BioHarvest Sciences Inc (NASDAQ:BHST) said its first full year as a Nasdaq-listed company was marked by revenue growth, expanding operations, and balance sheet improvements, according to a shareholder letter released on Wednesday by CEO Ilan Sobel. In the letter, Sobel outlined operating and financial progress made in 2025 and described the company's position entering 2026.
BioHarvest gets $1.6M Israeli grant to advance botanical synthesis technology
BioHarvest Sciences Inc (NASDAQ:BHST) said on Thursday it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA) to support the development of its second-generation Botanical Synthesis manufacturing process. The biotechnology company said the funding was approved under the IIA's Bio-Convergence program, which backs technologies combining biology, engineering, data science and artificial intelligence.
BioHarvest Sciences launches VINIA Blood Flow Hydration product in US market
BioHarvest Sciences Inc. (NASDAQ:BHST) has launched VINIA Blood Hydration, a new electrolyte product that incorporates the company's Piceid resveratrol ingredient. The launch marks BioHarvest's entry into the US hydration and electrolyte category, a market the company cites as worth about $13 billion.
BioHarvest Sciences Inc. (BHST) Q3 2025 Earnings Call Transcript
BioHarvest Sciences Inc. ( BHST ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Ilan Sobel - Chief Executive Officer Bar Dichter - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Nicholas Sherwood - Maxim Group LLC, Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Presentation Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
BioHarvest sciences posts Q3 revenue rise, launches new hydration product
BioHarvest Sciences Inc. (NASDAQ:BHST), a biotechnology company known for its patented Botanical Synthesis technology, reported a 39% increase in third-quarter revenue, driven by growth in its core VINIA capsule business and expanding contract development and manufacturing (CDMO) operations. Total revenues for the quarter ended September 30 rose to $9.1 million, in line with management guidance.
BioHarvest Sciences raises $19.9M in public offering to fund expansion
BioHarvest Sciences Inc. (NASDAQ:BHST), a company developing its patented Botanical Synthesis technology platform, said on Monday it has completed an underwritten public offering of 2.85 million shares of common stock at $7 per share, generating gross proceeds of $19.9 million. The company said it plans to use the net proceeds for manufacturing expansion, research and development, marketing, debt reduction or refinancing, other capital expenditures, and general corporate purposes, including working capital.
BioHarvest Sciences to raise $17.4M in upsized public equity offering
BioHarvest Sciences Inc. (NASDAQ:BHST) announced that it has priced its underwritten public offering of 2,485,000 company shares at $7.00 per share, for expected gross proceeds of about $17.4 million. The company said it expects to use the net proceeds from the offering for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or debt refinancing, capital expenditures, and general corporate purposes, including funding working capital.
BioHarvest Sciences CEO discusses Saffron Tech partnership - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel talked with Proactive about the company's new partnership with Saffron Tech aimed at developing a high-value saffron-based nutraceutical. Sobel explained that Saffron Tech, an Israeli firm, has pioneered an indoor horticultural system for growing first-grade saffron — known as "red gold" — which retails for up to $10,000 per kilo.
BioHarvest Sciences Inc. (BHST) Virtual Investor Webinar Call (Transcript)
BioHarvest Sciences Inc. (NASDAQ:BHST ) Virtual Investor Webinar Conference September 10, 2025 01:00 PM ET Company Participants Ilan Sobel - Chief Executive Officer Zaki Rakib - Co-Founder, Executive Chairman & President Conference Call Participants Nicholas Sherwood - Maxim Group LLC, Research Division Hunter Diamond - Diamond Equity Research LLC Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Alec Legg - Canaccord Genuity Corp., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Good day, and welcome to the BioHarvest Sciences Virtual Investor Webinar. Today's webinar is being recorded.
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.04 per share a year ago.
